235 related articles for article (PubMed ID: 21975125)
1. Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
Sides MD; Block GJ; Chadwick RW; Shan B; Flemington EK; Lasky JA
Virol J; 2011 Oct; 8():461. PubMed ID: 21975125
[TBL] [Abstract][Full Text] [Related]
2. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.
Sides MD; Block GJ; Shan B; Esteves KC; Lin Z; Flemington EK; Lasky JA
Virology; 2011 Jul; 416(1-2):86-97. PubMed ID: 21605886
[TBL] [Abstract][Full Text] [Related]
3. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
Frappier L
Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.
Sivachandran N; Sarkari F; Frappier L
PLoS Pathog; 2008 Oct; 4(10):e1000170. PubMed ID: 18833293
[TBL] [Abstract][Full Text] [Related]
5. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma.
Sivachandran N; Dawson CW; Young LS; Liu FF; Middeldorp J; Frappier L
J Virol; 2012 Jan; 86(1):60-8. PubMed ID: 22013060
[TBL] [Abstract][Full Text] [Related]
6. Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Yeung PL; Denissova NG; Nasello C; Hakhverdyan Z; Chen JD; Brenneman MA
J Cell Biochem; 2012 May; 113(5):1787-99. PubMed ID: 22213200
[TBL] [Abstract][Full Text] [Related]
7. Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.
Zebboudj A; Maroui MA; Dutrieux J; Touil-Boukoffa C; Bourouba M; Chelbi-Alix MK; Nisole S
Biochimie; 2014 Dec; 107 Pt B():247-56. PubMed ID: 25241256
[TBL] [Abstract][Full Text] [Related]
8. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
9. Assembly of Epstein-Barr Virus Capsid in Promyelocytic Leukemia Nuclear Bodies.
Wang WH; Kuo CW; Chang LK; Hung CC; Chang TH; Liu ST
J Virol; 2015 Sep; 89(17):8922-31. PubMed ID: 26085145
[TBL] [Abstract][Full Text] [Related]
10. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
11. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
12. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
13. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
14. Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.
Song H; Boo JH; Kim KH; Kim C; Kim YE; Ahn JH; Jeon GS; Ryu H; Kang DE; Mook-Jung I
Cell Death Differ; 2013 Apr; 20(4):639-48. PubMed ID: 23306558
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies.
Sivachandran N; Cao JY; Frappier L
J Virol; 2010 Nov; 84(21):11113-23. PubMed ID: 20719947
[TBL] [Abstract][Full Text] [Related]
16. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
17. Role of nuclear bodies in apoptosis signalling.
Krieghoff-Henning E; Hofmann TG
Biochim Biophys Acta; 2008 Nov; 1783(11):2185-94. PubMed ID: 18680765
[TBL] [Abstract][Full Text] [Related]
18. Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?
Borden KL
Biochim Biophys Acta; 2008 Nov; 1783(11):2145-54. PubMed ID: 18616965
[TBL] [Abstract][Full Text] [Related]
19. Functional reorganization of promyelocytic leukemia nuclear bodies during BK virus infection.
Jiang M; Entezami P; Gamez M; Stamminger T; Imperiale MJ
mBio; 2011; 2(1):e00281-10. PubMed ID: 21304169
[TBL] [Abstract][Full Text] [Related]
20. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
